TQB3824 / Sino Biopharm - LARVOL DELTA

A Clinical Study of TQB3824 in Subjects With Advanced Cancer (clinicaltrials.gov) - P1; N=65; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial • Oncology

[VIRTUAL] Preclinical candidate TQB3824, a small molecule inhibitor of CDC7, shows strong antitumor efficacy in colorectal and pancreatic tumor models (AACR 2021) - "We have identified a novel potent CDC7 inhibitor TQB3824, which shows high antitumor efficacy in CDC7 overexpressed solid tumor models. TQB3824 represents a promising clinical candidate for treating solid tumors with high CDC7 expression."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS • MCM2